Emerging orthobunyaviruses associated with CNS disease

Arthur Wouter Dante Edridge, Lia van der Hoek

1 Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam institute for Infection & Immunity, Amsterdam UMC, University of Amsterdam, the Netherlands, 2 Global Child Health Group, Emma Children’s Hospital, Amsterdam UMC, University of Amsterdam, the Netherlands

* a.w.edridge@amsterdamumc.nl

Abstract

The Orthobunyavirus genus comprises a wide range of arthropod-borne viruses which are prevalent worldwide and commonly associated with central nervous system (CNS) disease in humans and other vertebrates. Several orthobunyaviruses have recently emerged and increasingly more will likely do so in the future. Despite this large number, an overview of these viruses is currently lacking, making it challenging to determine importance from a One Health perspective. Causality is a key feature of determining importance, yet classical tools are unfit to evaluate the causality of orthobunyaviral CNS disease. Therefore, we aimed to provide an overview of orthobunyaviral CNS disease in vertebrates and objectify the causality strength of each virus. In total, we identified 27 orthobunyaviruses described in literature to be associated with CNS disease. Ten were associated with disease in multiple host species of which seven included humans. Seven viruses were associated with both congenital and postnatal CNS disease. CNS disease-associated orthobunyaviruses were spread across all known Orthobunyavirus serogroups by phylogenetic analyses. Taken together, these results indicate that orthobunyaviruses may have a common tendency to infect the CNS of vertebrates. Next, we developed six tailor-made causality indicators and evaluated the causality strength of each of the identified orthobunyaviruses. Nine viruses had a ‘strong’ causality score and were deemed causal. Eight had a ‘moderate’ and ten a ‘weak’ causality score. Notably, there was a lack of case-control studies, which was only available for one virus. We, therefore, stress the importance of proper case-control studies as a fundamental aspect of proving causality. This comprehensible overview can be used to identify orthobunyaviruses which may be considered causal, reveal research gaps for viruses with moderate to low causality scores, and provide a framework to evaluate the causality of orthobunyaviruses that may newly emerge in the future.

Author summary

Orthobunyaviruses are commonly implicated as causes of CNS disease. Well known examples include La Crosse virus, the primary cause of encephalitis in children in the
United States, and Schmallenberg virus, responsible for causing large outbreaks of CNS defects in newborn ruminants in Europe and Asia. In addition, several other less-known and novel orthobunyaviruses have also been implicated in CNS disease, yet association does not imply causality. Considering that nearly one hundred orthobunyaviruses are known to date and more are discovered every year, it is important to determine which orthobunyaviruses are relevant in the context of CNS disease, yet an overview of such information was lacking. To solve this problem, we first identified all orthobunyaviruses associated with CNS disease in literature and subsequently—given that the classical causality indicators are unfit for orthobunyaviral CNS disease—evaluated the strength of causality for each virus using tailor-made causality indicators. The results provide a comprehensible overview of orthobunyaviral CNS disease which can be used to guide future research.

Introduction

The Orthobunyavirus genus comprises a wide range of arthropod-borne viruses which are prevalent worldwide and are commonly associated with severe disease in humans and other vertebrates [1]. One of the most severe types of orthobunyaviral disease are those of the central nervous system (CNS). A well-known example is La Crosse virus, the most common cause of paediatric encephalitis in the United States [2].

CNS disease associated with orthobunyaviruses can generally be classified into two types: congenital and postnatal. In humans, postnatal CNS disease is most commonly observed, such as meningitis and encephalitis [2,3], but only limited evidence exists for congenital disease [4]. In non-human vertebrates, on the other hand, congenital CNS disease is more common, such as hydranencephaly (absence of the cerebral hemispheres) in newborn ruminants [5], but postnatal disease is reported as well, often in the same species in which congenital disease is described [6]. In addition, some viruses are implicated in postnatal disease in one host (mostly humans) and in congenital disease in another host [7]. Combined, these data suggest that these two types of disease may be related.

A multitude of novel orthobunyaviruses have recently emerged [5,8] and several factors indicate that increasingly more will be discovered in the future. The latest report of the International Committee on Taxonomy of Viruses indicates that the number of recognized orthobunyavirus species has nearly doubled, from 49 in 2011 to 87 in 2019 [9]. This increase may be due to an actual increase in the rate of emergence, driven by factors such as mass animal farming, deforestation and climate change [10]. On the other hand, more viruses may currently be detected because the tools for detection have improved during the last decade [11,12].

With 87 recognized species and 214 named orthobunyaviruses known to date [9], there is a need to determine which viruses are relevant in a One Health context. The outbreak of the Schmallenberg virus in ruminants in Europe late 2011—causing foetal malformations and affecting more than 5,000 farms—demonstrated that emerging novel orthobunyaviruses can cause substantial problems in a short amount of time [13]. One of the key factors in determining which pathogens to focus on, is the ability to cause disease. Many orthobunyaviruses have been associated with CNS disease, however, evidence of viral infection does not implicate causality, and an overview of the causality evidence for orthobunyaviral CNS disease is lacking.

Historically, causality is proven by fulfilling all the Henle-Koch postulates [14]. Many of these postulates cannot be applied to orthobunyaviral CNS disease (e.g. all infected individuals should develop the disease which does not allow asymptomatic infections), are unethical (e.g. require healthy individuals to be inoculated by potentially lethal pathogens) or lack the
specificity to evaluate features specific for viral CNS infections (e.g. localizing a pathogen to the CNS would support causality). More recently, a multitude of different postulates or ‘causality indicators’ for infectious diseases have been proposed, but a consensus on a definitive subset is lacking [15]. Consequently, there is a need for disease-specific causality indicators which allows evaluation of the strength of causality on a continuous scale, rather than a dichotomous result (i.e. causal or not causal).

The aim of this study was to provide an overview of orthobunyaviral CNS disease in vertebrates and objectify the strength of causality for each virus. We screened literature reporting cases of CNS infections where orthobunyaviruses were implicated as a potential cause and developed tailor-made causality indicators to suit orthobunyaviral CNS disease. For each of the orthobunyaviruses, we subsequently collected additional metadata to score each of the causality indicators and evaluate the evidence for causality.

Methods
Orthobunyavirus literature search
A literature search was performed in PubMed using a combination of the search terms on orthobunyaviruses and CNS diseases. References of all sources were checked for additional eligible articles. In addition, several textbooks and reviews on orthobunyaviruses and arbovirology were consulted. Primary sources (articles describing cases of orthobunyaviral CNS infections) were preferred but if not available, secondary sources (e.g. reviews) were also included. Viruses were considered to be associated with CNS disease when mentioned as such in the primary source or when patients demonstrated clear symptoms (decreased consciousness, personality changes, seizures, focal neurologic deficits or meningism) suggesting CNS involvement; i.e. patients with only a headache were not included. Viruses that only gave CNS disease upon experimental intracerebral inoculation were not included as this does not mimic natural infection, which requires that a virus, among other features, has to enter and traverse the body and cross the blood-brain barrier, which many pathogens cannot.

Causality indicators and virus-specific data retrieval on causality indicators
Previously described causality indicators [15] were reviewed for their fitness to evaluate the association between orthobunyaviruses and CNS disease. Minor modifications to the causality indicators were allowed to make them more specific to orthobunyaviral CNS infections. For each of these specific causality indicators, criteria were established to quantify to which extent they were met. Data on each of the causality indicators, on natural host range and geographic distribution was collected through virus-specific additional literature searches and from the Centers for Disease Control Arbovirus Catalogue (ArboCat). Causality was reviewed from a viral perspective, as such, results of different types of CNS disease (e.g. congenital and postnatal) in different host species (e.g. humans and other vertebrates) were combined for a single virus. When multiple results were available per causality indicator (e.g. when different species were experimentally infected), the result which provided the highest score was chosen. To facilitate interpretation, we finally combined all the causality indicators to a total causality score per virus, and grouped the scores into three categories of causality strength: ‘weak’, ‘moderate’ and ‘strong’.

Results
Primary literature review results
Of the 214 named orthobunyaviruses that are currently recognized [9], we identified 27 linked to CNS disease in vertebrates (Table 1). Seven viruses were linked to disease in humans and
Table 1. Orthobunyaviruses associated with CNS infections in humans and other vertebrates.

| Sero | Virus         | Risk group | Human CNS disease | Non-human vertebrate CNS disease |
|------|---------------|------------|-------------------|----------------------------------|
|      |               |            | Postnatal         | Congenital                       | Postnatal | Congenital |
|      |               |            | N Disease N Host  | Description* N Disease N         |           |           |
| Anop A | TCMV         | Adults     | Deep coma 1       |                                  |           |           |
| Bunyamwera | BATV     | Adults     | Sero/Postnatal    | 2 Horses Unspecified CNS disease 2 Abortion† 1 |           |           |
|      | CVV           | Adults     | Enc, acute/chronic men 4 Macro 2 Sheep HE 5 outbreaks |           |           |
|      | GERV          | Adults     | Mental confusion 1 |                                  |           |           |
|      | GROV          | Adults     | Prostration, paresis 4 |                                  |           |           |
|      | ILEV          | Adults     | ME 1              |                                  |           |           |
|      | MDV           | Adults     | Unspecified CNS disease 1 Horses EM 6 |           |           |
|      | TENV          | Adults     | Enc 1 Micro, macro 0† Foxes Rabies like symptoms 1 |           |           |
|      | TCV           | Children   | ME 1              |                                  |           |           |
| California | CEV       | Children, adults | Enc 4§ Horses Enc 2 |                                  |           |           |
|      | CHATV         | Adults     | Disorientation, nuchal rigidity 2 |                                  |           |           |
|      | INKV          | Children, adults | Enc, men, polyradiculoneuritis 32 |                                  |           |           |
|      | JCV           | Mostly adults | Men, ME 190* |                                  |           |           |
|      | LACV          | Mostly children | Enc, men, ME 1,045† Dogs Men, necrotizing encephalopathy 3 |           |           |
|      | SHHV          | Mostly children | Enc, ME 8** Horses Enceph. 2 |                                  |           |           |
|      | TAHV          | Children, adults | Enc, men, ME, chronic†† |                                  |           |           |
|      | TVTV          | Adults     | Paralysis 1       |                                  |           |           |
| Nyando | KKV           |            | Bats Unspecified CNS disease 12 |                                  |           |           |
| Sambu | AINOV         |            | Cows HE Few outbreaks |                                  |           |           |
|      | AKAV          |            | Cows, sheep, goats, pigs EM (cows) Regular outbreaks HE (all) 42,000†† |           |           |           |
|      | OROV          | Adults     | Enc, men >25      |                                  |           |           |
|      | SBV           |            | Cows, sheep, goats HE >5,000 farms†† |                                  |           |           |
|      | SHAV          |            | Cows HE 15 |                                  |           |           |
|      | SHUV          |            | Cows, horses, sheep, goats Enc, ME (horses, cows) 7 (5 horses, 2 cows) HE (ruminants) Few outbreaks |           |           |
| Turlock | TURV*        |            | Ostriches EM 1    |                                  |           |           |
| Unc   | NTWV          | Children   | Enc 1              |                                  |           |           |

Ref, references; Sero, serogroup; Anop A, Anopheles A; Unc, Uncategorized; N, number of cases of CNS disease with acute infection described in literature unless otherwise specified; CEV, California encephalitis virus; CHATV, chatanga virus; GROV, Guaroa virus; INKV, Inkoo virus; JCV, Jamestown Canyon virus; LACV, La Crosse virus; SSJV, snowshoe hare virus; TAHV, Tahyha virus; TVTV, trivittatus virus; AINOV, Aino virus; AKAV, Akabane virus; OROV, Oropouche virus; SBV, Schmallenberg virus; SHAV, Shamaunda virus; SHUV, Shuni virus; BATV, Batai virus; BUNV, Bunyamwera virus; CVV, Cache Valley virus; GERV, Germiston virus; ILEV, Ilesha virus; MDV, Main Drain virus; KKV, Kaeng Khoi virus; TENV, Tensaw; TCMV, Tacaiuma virus; TUCV, Tucunduba virus; TURV, Turlock virus; NTWV, Ntwetwe virus; Enc, encephalitis; Men, meningitis; ME, meningoencephalitis; EM, encephalomyelitis; Macro, macrocephaly; Micro, microcephaly; HE, hydranencephaly. Blue: associated with human CNS disease only, red: associated with non-human CNS disease only and green: associated with human and non-human vertebrate CNS disease.

† As described by the author.

‡ Virus detected in the brain of the aborted horse.

§ Disease association based on a significantly higher prevalence of antibodies (any type) in the mother of micro- and macrocephalic newborns than healthy newborns, however, no cases of acute infection described.

¶ 504 cases described by one source[32], these were not included as they were likely associated with another virus from the same serogroup.

# Cases reported in the US between from 2004 to 2018.

"Cases reported in the US between from 2004 to 2018.

** Cases described in Canada.

†† Also associated with several chronic neurologic infections[63]

‡‡ Number of abnormal calves born between 1972 and 1975 in Japan.

§§ Number of farms reporting cases of SBV-associated congenital disease from December 2011 until May 2012.

¶¶ The virus isolated from the ostrich was a Turlock-like virus, for this review considered as Turlock virus itself.

https://doi.org/10.1371/journal.pntd.0008856.t001
other vertebrates, 12 in humans alone and eight in non-human vertebrates alone. Non-human vertebrates with CNS disease included ruminants (cows, goats and sheep), horses, canines (dogs and foxes), bats, seals and ostriches. For humans, postnatal CNS disease was observed for all human-associated viruses, and congenital disease (together with postnatal CNS disease) only for Cache Valley virus and Tensaw virus. For non-human vertebrates, postnatal disease (11 of 15) and congenital disease (8 of 15) distributed nearly equally. The 27 orthobunyaviruses were found around the world, yet each virus had their specific geographic distribution, dictated by their vertebrate and arthropod host ranges. Phylogenetic analysis revealed that the viruses associated with CNS infections distributed across the known diversity of Orthobunyavirus serogroups and did not cluster in a monophyletic clade (Fig 1).

**Causality indicator selection**

Twenty-five previously described causality indicators [15] were reviewed on their fitness to assess the causality of orthobunyaviral CNS infections in vertebrates (Table 2). Based on these indicators, six orthobunyaviral CNS disease indicators were developed as described below. For each of these six causality indicators, criteria were established to score to which extent each indicator was satisfied (range 0 to 3, Table 3).

The first causality indicator compares the prevalence of acute infection in cases and healthy controls. Knowing that orthobunyaviruses can cause asymptomatic infections and that many other pathogens can also cause CNS infections, this indicator does not require the virus to be absent in controls, nor present in all cases. Instead, a significantly higher prevalence in cases than controls is considered as the strongest evidence (3 points). For cohorts without a control group, we determine that a certain prevalence, although suboptimal, can still support causality when a virus was localized to the CNS (see Discussion). Given that outbreaks in livestock are more likely to result in a higher prevalence because of their shared risk profile and close proximity, we consider that the threshold for prevalence in livestock should be higher to reach the same score. For livestock, the prevalence thresholds are >10% (1 point) and >50% (2 points). For other vertebrates, the thresholds are >1% (1 point) and >5% (2 points), with at least 2 positive cases.

Diagnostic methods for virus identification are assessed by the second indicator. We regard serological identification to be a weaker method (1 point) as it leaves the possibility for cross-reactivity. Although cross-reactivity cannot be completely excluded (see Discussion), attempts to eliminate cross-reactivity by including other viruses within the same serogroup is superior (2 points). To exclude previous infections, all serologically identified infections had to be confirmed as being acute (to confirm a temporal association). Due to heterogeneity in criteria for an acute infection, the criteria as described in the original reference are followed. Genome detection or virus isolation is considered superior and is therefore given 3 points.

The third indicator evaluates the capability of inducing similar disease after experimental infection. This indicator is fully satisfied (3 points) when CNS disease is observed after inoculation of the same host species as the index case. When inoculated in a different species within the same taxonomic order, two points are scored. The lowest (1 point) score is awarded when disease develops in experimentally infected rodents. No points are given when CNS disease could only be elicited in suckling mice (in contrast to weanling and adult mice) as they are well-known amplifiers of any Bunyavirales species [69]. A fatal outcome is regarded equal to developing CNS disease because severe CNS infections often result in death and post-mortem studies to prove CNS pathology may not always be performed. Besides outcome, this indicator also considers the route of inoculation. An orthobunyavirus inoculated outside the CNS virus needs to cross the blood-brain barrier whereas an intracerebrally inoculated virus does not. Similarly, for congenital CNS infections, a virus inoculated in pregnant mothers needs to cross...
Fig 1. Phylogeny of 27 orthobunyaviruses linked to CNS disease in vertebrates. The tree is rooted by an outgroup of Herbeviruses (Tai virus, Herbert virus and Kibale virus), based on a recent phylogeny by Shchetinin et al. [64]. Nucleocapsid (S-segment) protein sequences were retrieved from reference phylogeny, and if not available, from GenBank (preferably RefSeq or Swiss-Prot). Protein sequences were aligned using M-Coffee and only columns with scores of 5 or higher were retained. A Maximum-Likelihood model with LG + G + I, complete deletion and a bootstrap of 1000 was used to infer the phylogeny in Mega v10. The phylogeny contains at least one virus from each of the known orthobunyavirus serogroups, in grey are representative viruses from serogroups without any virus linked to CNS disease. Between brackets: number of viruses associated with CNS infection in each specific serogroup. Coloured branches correspond to specific serogroups. Only Maximum Likelihood bootstrap values $>50\%$ are displayed. Pictograms indicate hosts associated with CNS disease, orange: postnatal disease, blue: congenital disease. Abbreviations describe the known host range (not per se requiring association with CNS disease), obtained from ArboCat [65] and other sources [30,66–68].

https://doi.org/10.1371/journal.pntd.0008856.g001
The placenta in contrast to intrauterine inoculated viruses. Following this reasoning, intracerebrally or intrauterine inoculated viruses are scored one point lower.

The localization of the virus, the fourth causality indicator, is another important feature of causality. The highest score is awarded for viruses visualized intracellularly in the CNS (3 points) or when detected from brain biopsies. Two points are given when viruses are detected in CSF, which is scored lower because a virus may have 'leaked' into the CSF because of a disrupted blood-brain barrier, carried by migrating lymphocytes (e.g. Oropouche virus is known

### Table 2. Classical causality indicators and fitness for orthobunyaviral CNS disease.

| Causality indicator                                                                 | Fit | Reason for unfitness or modified causality indicator (CI)                                      |
|------------------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------|
| Parasite occurs in every case of the disease under circumstances that could account for observed pathology. | M   | Higher prevalence in cases than controls (CI 1)                                               |
| Parasite is absent from those without the disease.                                  | M   | Higher prevalence in cases than controls (CI 1)                                               |
| It can be reproducibly grown in pure culture.                                      | F   | Could the virus be isolated? (CI 2)                                                           |
| It can induce the disease anew.                                                     | M   | Also allowing experimental infection of other species (CI 3)                                   |
| Specific virus must regularly be found associated with a disease.                   | U   | Orthobunyaviruses often cause asymptomatic infection                                          |
| Virus must be shown to occur in the sick individuals but not as an incidental or accidental finding, instead being the cause of the disease under investigation. | U   | Orthobunyaviruses often cause asymptomatic infection                                          |
| New virus established by laboratory passage (animal/tissue culture).                | F   | Could the virus be isolated? (CI 2)                                                           |
| Repeatedly isolated from human specimen and not a contaminant derived from host used to propagate the virus. | U   | Unfavourable for rare or novel viruses                                                        |
| Antibody response increasing as a result of infection.                             | F   | Included as diagnosis by serological criteria (CI 2)                                           |
| Agent compared with other similar viruses.                                          | F   | Additional information congruent with biological knowledge (CI 6)                            |
| Constant association with specific illness.                                        | U   | Orthobunyaviruses often cause asymptomatic infection                                          |
| Double blind studies with human volunteers should reproduce clinical disease.      | M   | Also allowing experimental infection of other species (CI 3)                                   |
| Cross-sectional and longitudinal studies to identify patterns of disease.          | F   | Use of syndrome-based studies not limited to infected persons (CI 1)                           |
| Preventable by use of specific vaccine.                                            | U   | No vaccine available                                                                           |
| Nucleic acid sequence belongs to a putative pathogen and is present in most cases of an infectious disease preferentially associated with pathology. | M   | Higher prevalence in cases than controls (CI 1)                                               |
| Lower copy number or absence of these sequences from those without disease.        | M   | Higher prevalence in cases than controls (CI 1)                                               |
| Decrease or absence following treatment/recovery.                                  | U   | No treatment available                                                                         |
| Detection predates disease or sequence copy number correlated with severity.        | U   | Asymptomatic orthobunyaviral infection can have significant viraemia                           |
| Congruence with biological knowledge.                                              | F   | Was additional information in line with a viral CNS infection? (CI 6)                          |
| Correlation with areas of tissue pathology.                                        | F   | Was additional information in line with a viral CNS infection? (CI 6)                          |
| Reproducible findings.                                                             | U   | Unfavourable for rare or novel viruses                                                         |
| Sequencing microbial community.                                                    | M   | Metagenomic sequencing to exclude other pathogens (CI 5)                                      |
| Computational models to assess presence and proportion for resulting pathology.     | M   | Not applicable to orthobunyaviruses                                                            |
| Isolation of microbes of interest from diseased host.                              | F   | Could the virus be isolated? (CI 2)                                                            |
| Testing of fresh isolates and consortia in relevant disease model.                 | F   | Did experimental infection lead to similar symptoms (CI 3)                                     |

Adapted from Antonelli et al. [15]. M, modified; F, fit; U, unfit. The number in bracket describes for which orthobunyaviral CNS disease specific CI (Table 3) this classical CI was used.

https://doi.org/10.1371/journal.pntd.0008856.t002
to infect leukocytes [70]) or because the CSF may have been contaminated with virus-containing blood during lumbar puncture. Viruses detected outside the CNS are given the lowest score (1 point).

The fifth causality indicator determines the exclusion of alternative aetiologies. Although this criterion was not specifically described in the original list, we consider this to be of importance as CNS disease can be caused by many pathogens. We regard the exclusion of three or more pathogen types (viruses, bacteria, fungi, parasites and prions) as the highest score (3 points), two pathogen types one point lower, and only one type of pathogen the lowest score (1 point). If a more likely alternative aetiology is identified, no points are awarded. When histopathological evidence suggests a viral cause and multiple alternative viral aetiologies are excluded, three points are awarded.

Causality indicator six evaluates whether additional evidence, congruent with the biological knowledge, is available to support an orthobunyavirus CNS infections. Brain tissue showing pathological changes indicative of a viral infection is considered as the strongest evidence (3 points). Brain imaging or immune profiling is also considered but regarded as less specific and therefore scored lower (2 points). EEG pattern indicative of a focal encephalopathy results in one point.

Causality evaluation

Using the above mentioned causality indicators, we scored the 27 orthobunyaviruses associated with CNS infections in vertebrates (Table 4). The total causality scores ranged from 3 to
Table 4. Causality scores for orthobunyavirus associated with CNS infections in vertebrates.

| Virus   | 1. Prevalence of acute infection in symptomatic versus control cohort (number of total cases studied) | 2. Virus detection determined by | 3. Experimental infection producing disease in | 4. Virus localized in | 5. Which other pathogen types were excluded | 6. Additional evidence supporting viral CNS infection | Total score | Ref |
|---------|------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------------------|----------------------|------------------------------------------|-----------------------------------------------|------------|-----|
| AKAV    | 3 88% (59) vs 27% (11)†                           | Isolation                       | Pregnant cows IV                           | CNS cells            | 3 Viruses†                                | 3 Histopathology                              | 18         | Strong [6,23,7,12] |
| LACV    | 1 8–30%, no controls, ex CNS                      | Isolation                       | Puppies IV                                 | CNS cells            | 3 >2 pathogen types                       | 3 Histopathology                              | 16         | [2,62,73–75] |
| AINOV   | 0 10% (30), no controls, ex CNS                    | Isolation                       | Pregnant cows IV                           | CNS cells            | 3 Viruses†                                | 3 Histopathology                              | 15         | [50,76–78] |
| BUNV    | 0 NR                                              | Isolation                       | Humans IV†                                 | Brain tissue         | 3 >2 pathogen types                       | 3 Histopathology                              | 15         | [20,79] |
| CVV     | 0 NR                                              | Isolation                       | Pregnant sheep IU                          | CNS cells            | 3 >2 pathogen types†                      | 3 Histopathology                              | 14         | [21,22,80] |
| SIV     | 1 41% (54), no controls, in CNS                    | Isolation                       | Adult mice SC                              | CNS cells            | 3 >2 pathogen typesº                      | 3 Histopathology                              | 14         | [5,36,8,383] |
| SHUV    | 2 100% (15), no controls, in CNS                   | Isolation                       | Newborn mice IP                           | Brain tissue         | 3 >2 pathogen types                       | 3 Histopathology                              | 13         | [59,60,65] |
| TURV    | 0 5% (20), no controls, in CNS                     | Isolation                       | Weanling mice IP                          | Brain tissue         | 3 >2 pathogen types                       | 3 Histopathology                              | 13         | [62,65] |
| JCV     | 0 NR                                              | PCR                             | Weanling mice IP                           | Brain tissue         | 3 >2 pathogen types                       | 3 Histopathology                              | 13         | [65,84] |
| BATV    | 0 NR                                              | Isolation                       | Weanling mice ICU                         | CNS cells            | Viruses†                                  | 3 Histopathology                              | 12         | Moderate [18,65] |
| OROV    | 1 3% (110), no controls, in CNS                    | PCR                             | Adult hamster SC                          | CSF                  | 3 >2 pathogen typesº                      | 2 CT                                           | 12         | [85–87] |
| SHAV    | 0 NR                                              | Isolation                       | Newborn mice IP                           | Brain tissue         | 3 Viruses†                                | 3 Histopathology                              | 12         | [58,65] |
| NTWV    | 0 NR                                              | PCR                             | Newborn mice IP                           | Brain tissue         | 3 Viruses†                                | 3 Histopathology                              | 12         | [49,65] |
| SSHV    | 0 NR                                              | PCR                             | Newborn mice IP                           | Brain tissue         | Viruses                                   | 2 Immune profiling                            | 10         | [8] |
| KKV     | 2 92% (12) vs 0% (1), in CNSº                      | Isolation                       | Newborn mice IP                           | Brain tissue         | Lysavirus                                 | 0                                               | 9          | [47,65,88] |
| MDV     | 0 NR                                              | PCR                             | Newborn mice IP                           | Brain tissue         | Viruses                                   | 8                                               | 8          | [31,89] |
| INKV    | 1 20% (10), no controls, ex CNS                    | PCR                             | Newborn mice IP                           | Outside CNS          | Viruses                                    | 3 Histopathology                              | 10         | [47,65,88] |
| ILEV    | 0 NR                                              | PCR                             | Newborn mice SC                           | CSF                  | 3 Viruses†                                | 0                                               | 6          | [29,65] |
| TAHV    | 0 10% (10), no controls, ex CNSº                   | PCR                             | Newborn mice IP                           | Outside CNS          | Viruses                                    | 6                                               | 6          | [38,65,90] |
| CEV     | 0 1% (188), no controls, ex CNS                   | PCR                             | Newborn mice SC                           | CSF                  | 2 Viruses and bacteria                     | 1 EEG                                           | 7          | [37,65,90] |
| TENV    | 0 0% (1,739)º, no controls                        | Isolation                       | Newborn mice SC                           | Brain tissue         | Viruses                                   | 1 Viruses                                     | 6          | [35,36,91,92] |
| CHATV   | 0 0% (4,214)º, no controls, ex CNS                | PCR                             | Newborn mice SC                           | Outside CNS          | Viruses                                    | 1 Viruses                                     | 6          | [32,33,65] |
| TCMV    | 0 NR                                              | PCR                             | Newborn mice IP                           | Outside CNS          | Viruses and bacteria                       | 2 Viruses and bacteria                         | 6          | [37] |
| GROV    | 0 NR                                              | PCR                             | Newborn mice SC                           | Outside CNS          | Viruses                                   | 4                                               | 4          | [16,65] |
| TCVV    | 0 NR                                              | PCR                             | Newborn mice SC                           | Outside CNS          | Viruses                                   | 4                                               | 4          | [16,65] |
| GERV    | 0 NR                                              | PCR                             | Newborn mice SC                           | Outside CNS          | Viruses                                   | 0                                               | 4          | [28] |
| TVTV    | 0 NR                                              | PCR                             | Newborn mice SC                           | Outside CNS          | Viruses                                   | 0                                               | 4          | [26,65] |

Ref, references; IV, intravenous; IU, intrauterine; IP, intraperitoneal; SC, subcutaneous; IC, intracerebral.
†Viral cause deemed most likely by histopathology.
‡Of all encephalitis cases in USA in 1999.
§Deep sequencing was performed to aagnostically screen for different pathogen types.
¶Humans with inoperable neoplasms were inoculated to study potential oncolytic effects of this virus.
*Non-significant difference, p = 0.0034, Fisher’s exact test.
**Viral cause deemed most likely by histopathology.
††Deep sequencing was performed to aagnostically screen for different pathogen types.
‡‡Humans with inoperable neoplasms were inoculated to study potential oncolytic effects of this virus.
1. Prevalence of acute infection in symptomatic versus control cohort (number of total cases studied).
2. Virus detection determined by.
3. Experimental infection producing disease in.
4. Virus localized in.
5. Which other pathogen types were excluded.
6. Additional evidence supporting viral CNS infection.

Emerging orthobunyaviruses associated with CNS disease

https://doi.org/10.1371/journal.pntd.0008856.t004

the maximum of 18 points and were further narrowed into three categories: ‘weak’ (0–6 points), ‘moderate’ (7–12 points) and ‘strong’ (13–18 points). Akabane virus was the only virus that scored full points. Besides Akabane virus, La Crosse, Aino, Bunyamwera, Cache Valley, Schmallenberg, Shuni, Turlock-like and Jamestown Canyon virus all fell in the ‘strong’ causality category. Batai, Oropouche, Shamonda, Ntwetwe, Snowshoe Hare, Kaeng Khoi,
Main Drain and Inkoo virus were categorized as ‘moderate’, and Ilesha, Tahyna, California encephalitis, Tensaw, Chatanga, Tacaiuma, Guaroa, Tucunduba, Germiston and Trivitattus virus had a ‘weak’ evidence of causality.

**Discussion**

The large and increasing number of orthobunyaviruses associated with CNS disease makes it challenging to determine importance from a One Health perspective. A key feature of determining importance is causality, yet classical causality tests are unfit for orthobunyaviral CNS disease. We developed a list of tailored causality indicators, identified 27 orthobunyaviruses to be associated with CNS disease in vertebrates and evaluated their strength of causality. We identified several viruses with high causality scores which may be regarded as ‘causal’ and found numerous viruses with lower causality scores, for which we identify research gaps to focus on.

Eight orthobunyaviruses had a ‘strong’ causality score. These include Akabane, Aino, Shuni and Schmallenberg virus, commonly associated with congenital CNS malformations in ruminants. La Crosse, Jamestown Canyon, Cache Valley and Bunyamwera virus also belong to this group, which are mostly known for human postnatal disease. Akabane virus was the only virus able to completely satisfy all causality indicators. Indeed, for the other seven viruses, the lack of case-control studies is a limitation (discussed below), but also appropriate experimental infection studies were missing. Understandably, experimental infections may not have been performed because of ethical constraints—especially for humans—yet surprisingly, this has been done for Bunyamwera virus. One report describes the experimental infection of humans with inoperable neoplasms with Bunyamwera virus as a potential oncolytic therapy, morbidly resulting in a fatal encephalitis [79]. While performing such experiments may support causality, we evidently do not advocate this. Rather, we consider sufficient causality evidence is available for these viruses to consider them causal.

Viruses classified as having a ‘moderate’ causality score included some well- and lesser-known viruses associated with CNS disease in humans and other vertebrates. For most of these viruses no case-control studies were done, experimental infections were only successful in rodents, and almost no viruses were visualized intracellularly in the CNS. Interestingly, this group includes Shamonda virus, commonly described in bovine congenital CNS disease, but despite the high prevalence lacks causality evidence to be ‘strong’. We consider that these viruses with a ‘moderate’ score are possible causes of CNS infections. Nonetheless, this group also includes Snowshoe Hare and Inkoo virus, which have never been detected in the CNS and for which only serological evidence of infection exists, allowing misclassification because of cross-reactivity. Considering these limitations, we suggest that more research into causality should be done for this group of viruses.

The remaining ten viruses all scored poorly on most causality indicators resulting in a ‘weak’ causality score. They were all found in humans, although some were also mentioned in disease in other vertebrates. The majority of serologically diagnosed viruses fell into this category, which stresses the importance of direct virus detection (e.g. PCR or isolation), preferably on CNS samples to strengthen causality. Even though Ilesha and Tensaw virus were isolated from the CNS, they failed to perform well on all other causality indicators. An explanation for this could be that these viruses are relatively ‘old’—they were last implicated in CNS disease in 1964 [29], and 1965 [33] respectively—when several conventional assays which may support causality (e.g. PCR or in situ hybridization) were not available. Similarly, even for more recently detected viruses, some of these experiments may not yet have been performed. These low causality scores therefore do not exclude the possibility of causality.
Case-control studies, often referred to as ‘association-studies’, are a fundamental part of causality research. Only one proper case-control study has been done for the exposure to Aka-bane virus in diseased and healthy newborn calves. For cohorts of cases with CNS disease, the prevalence of a single cause is usually very low, as there is an extensive list of potential causes of CNS disease. In such cohorts of diseased cases, even a low prevalence can indicate causality, but may similarly be a result of unrelated (co-)infection as orthobunyaviruses may commonly cause asymptomatic infection. To account for this, comparing the prevalence to a cohort without the disease would strengthen causality. For example, 4,214 humans with a suspected CNS infection were tested for Chatanga virus of which 2 were positive by serological evidence of acute infection. Because no healthy control group was added, it remains difficult to evaluate a causal relationship. An exception could be made when the pathogen is detected in the CNS, which is generally considered a sterile site and presence of a pathogen is more likely to be symptomatic and causal. In addition, it has to be kept in mind that sampling of CNS material is unethical from healthy subjects, hindering case-control studies. On the other hand, obtaining serum samples from healthy matched controls is much easier. Therefore, for diagnostics using non-CNS derived samples like blood, we strongly recommend the use of properly designed case-control studies as a fundamental aspect of proving causality.

Detection of orthobunyaviruses is commonly based on serologic methods, mainly because of their wide availability and their extended window period compared to virus detection based methods. However, serological assays may significantly influence causality because of two potential problems: temporality and cross-reactivity. Most of the current evidence that orthobunyaviruses may cause congenital CNS malformations in humans is based on a study (on Cache Valley and Tensaw virus) describing a significantly higher seroprevalence in mothers of micro- and macrocephalic newborns than healthy controls [4]. Because IgG antibody levels were measured in this study, a temporal association between onset of infection and disease is lacking. Conversely, a study on human postnatal CNS disease and Jamestown canyon virus found a significantly lower seroprevalence of reactive antibodies in cases (8%) than controls (11%), which, using the same logic, could argue against causality [48]. For this reason, we only deemed serological diagnoses with confirmation of acute infections relevant for this manuscript.

A second issue with serological assays is the possibility of cross-reactivity. The orthobunyaviruses are commonly divided into serogroups of viruses with serological cross-reactivity. Whereas the specificity of serological assays has greatly increased over the last years, cross-reactivity can only be conclusively excluded when all other viruses within the same serogroup are tested for. Given that we identified nine viruses within the Bunyamwera serogroup to be associated with CNS infections (Table 1 and Fig 1), all of these should be included. One could argue that some of these viruses do not circulate in a certain region, at a given time or in a specific host, yet this knowledge may not always be available. For example, it is suggested that Jamestown Canyon virus infections in the United States have commonly been misclassified as La Crosse virus infections because of cross-reactivity [41].

It is important to note that several factors, such as the use of serological assays, but also differences in epidemiology and availability of research funding, have likely influenced the availability of causality evidence and subsequently the causality scores. The results of this study should therefore not be used to exclude causality of viruses with moderate or low causality scores. Rather, our study shows which viruses can be considered causal and reveals the knowledge gaps for the other viruses with lower causality scores, targets for future research.

One possible reason that many orthobunyaviruses (and other pathogens) are understudied is because of the large and increasing number of pathogens associated with CNS disease known to date. Testing for all pathogens using conventional diagnostics is impossible, and
therefore clinicians and researchers usually are limited to those with a high prevalence and ‘proven’ causality, further biasing the availability of causality evidence. This may, in part, even explain why the cause of CNS disease frequently remains unknown [93], if these understudied pathogens are responsible for disease but not tested for. One promising alternative virus detection method, which increases the diagnostic yield and removes bias against understudied viruses, is metagenomics. In theory, metagenomics allows for detection of all pathogens—including potentially novel pathogens—by agnostic sequencing of the genomic content in a sample [11,12].

The observation that CNS disease was associated to 8% of the known orthobunyaviruses (17 had a ‘moderate’ or ‘strong’ causality score of the 214 that are known) could indicate that only a few have the capability to cause CNS disease. On the other hand, these CNS disease-related viruses are not phylogenetically or serologically clustered (Fig 1), which may actually suggest that all orthobunyaviruses have an intrinsic ability to cause CNS disease. This is supported by studies which have shown that multiple viruses, including ones not implicated in natural CNS disease such as San Angelo virus, can replicate in brain tissue after intrauterine inoculation in sheep [89]. Furthermore, this ability may even be host-independent, as we observed ten viruses to be implicated in CNS disease in multiple hosts of which seven included humans.

Determining importance from a One-Health perspective is, next to causality, also determined by the burden of disease, which this review does not primarily address. We summarized the total number of cases of human CNS disease described in scientific literature (Table 1), but this is a large underrepresentation of the actual prevalence. Only the number of human La Crosse virus and Jamestown canyon virus infections described in literature may be informative, as they are based on proper epidemiological studies [3,40], yet similar studies were not available for the other orthobunyaviruses. In terms of severity of disease, human fatalities from CNS disease were described for Ilesha [29], Tucunduba [34], Ntwetwe [8], Jamestown Canyon [94] and La Crosse virus [95]. For the first three, these were the only reported cases of CNS disease, but for the latter two, fatalities were rare. With respect to human congenital disease, the burden of disease seems to be low, as abortions were not reported and malformations were only reported in two putative cases of neonatal macrocephaly for whom a maternal diagnostic antibody rise against Cache Valley virus was found during pregnancy [4].

For this review we used a ‘glass half-full’ approach, as we only regarded evidence which would support causality and, if multiple results were available, scored the results which would support causality best. Consequently, studies reporting negative results—arguing against causality—were not considered. This was done because a positive result generally proves ability (e.g. isolation proves viability), whereas a negative result does not necessarily exclude this (e.g. failure to culture a virus does not prove absence of a viable virus in the patient). For example, one report describes the inability to visualize Main Drain virus in the brains of horses from which the virus was repeatedly isolated despite extensive attempts [31]. This does not exclude viral CNS tropism as the virus may have left the brain during an earlier stage of disease. Clearly, including negative results into a causality model would strengthen its value but is arguably complicated, yet doing so would be a direction of future research.

According to our knowledge, this is the first complete overview of orthobunyaviruses associated with CNS disease and one of the first to systematically evaluate the causality of multiple pathogens associated to a specific disease. This comprehensible overview can be used to identify viruses which may be regarded as proven causal, reveal research gaps for viruses with low causality scores and provides a framework to evaluate the causality of orthobunyaviruses that may newly emerge.
Acknowledgments

We thank Emmanuel Nakoune and Sergey Alkhovsky for providing source material for the review, Alexander Pasternak for his help with Russian translations, and Cormac Kinsella for sharing data on the prevalence of Jamestown Canyon virus cases in the United States.

Author Contributions

Conceptualization: Arthur Wouter Dante Edridge.

Investigation: Arthur Wouter Dante Edridge.

Methodology: Arthur Wouter Dante Edridge.

Supervision: Lia van der Hoek.

Writing – original draft: Arthur Wouter Dante Edridge.

Writing – review & editing: Lia van der Hoek.

References

1. Elliott RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014; 12: 673–685. https://doi.org/10.1038/nrmicro3332 PMID: 25198140

2. Rust RS, Thompson WH, Matthews CG, Beaty BJ, Chun RW. La crosse and other forms of California encephalitis. J Child Neurol. 1999; 14: 1–14. https://doi.org/10.1177/088303739901400101 PMID: 10025535

3. Pastula DM, Hoang Johnson DK, White JL, Dupuis AP, Fischer M, Staples JE. Jamestown canyon virus disease in the United States-2000-2013. Am J Trop Med Hyg. 2015; 93: 384–389. https://doi.org/10.4269/ajtmh.15-0196 PMID: 26033022

4. Calisher CH, Sever JL. Are North American Bunyamwera serogroup viruses etiologic agents of human congenital defects of the central nervous system? Emerg Infect Dis. 1995; 1: 147–151. https://doi.org/10.3201/eid0104.950409 PMID: 8903187

5. Hoffmann B, Scheuch M, Höper D, Jungblut R, Holstege M, Schirrmacher H, et al. Novel orthobunyavirus in cattle, Europe, 2011. Emerg Infect Dis. 2012; 18: 469–472. https://doi.org/10.3201/eid1803.111905 PMID: 22376991

6. Kono R, Hirata M, Kaji M, Goto Y, Ikeda S, Yanase T, et al. Bovine epizootic encephalomyelitis caused by Akabane virus in southern Japan. BMC Vet Res. 2008; 4. https://doi.org/10.1186/1746-6148-4-20 PMID: 18554406

7. Edwards JF, Livingston CW, Chung SI, Collisson EC. Ovine Arthrogryposis and Central Nervous System Malformations Associated with in utero Cache Valley Virus Infection: Spontaneous Disease. Vet Pathol. 1989; 26: 33–39. https://doi.org/10.1177/030098588902600106 PMID: 2492399

8. Edridge AWD, Deijs M, Namazzi R, Cristella C, Jebbink MF, Maurer I, et al. Novel Orthobunyavirus Identified in the Cerebrospinal Fluid of a Ugandan Child With Severe Encephalopathy. Clin Infect Dis. 2019;68. https://doi.org/10.1093/cid/ciy486 PMID: 29893821

9. Abudurexiti A, Adkins S, Alioto D, Alkhovsky S V., Avsič-Županc T, Ballinger MJ, et al. Taxonomy of the order Bunyavirales: update 2019. Arch Virol. 2019; 164: 1949–1965. https://doi.org/10.1007/s00705-019-04253-6 PMID: 31065850

10. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004. pp. 242–249. https://doi.org/10.1038/nature02759 PMID: 15241422

11. Edridge Deijs, van Zeggeren Kinsella, Jebbink Bakker, et al. Viral Metagenomics on Cerebrospinal Fluid. Genes (Basel). 2019; 10: 322. https://doi.org/10.3390/genes10050322 PMID: 31052348

12. Wilson MR, Sample HA, Zorn KC, Arevalo S, Yu G, Neuhaus J, et al. Clinical metagenomic sequencing for diagnosis of meningitis and encephalitis. N Engl J Med. 2019; 380: 2327–2340. https://doi.org/10.1056/NEJMoa1803396 PMID: 31189036

13. Beer M, Conraths FJ, van der Poel WHM. ‘Schmallenberg virus’—a novel orthobunyavirus emerging in Europe. Epidemiol Infect. 2013; 141: 1–8. https://doi.org/10.1017/S0950268812002245 PMID: 23046821

14. Evans AS. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med. 1976; 49: 175–195. PMID: 782050
15. Antonelli G, Cutler S. Evolution of the Koch postulates: towards a 21st-century understanding of microbial infection. Clin Microbiol Infect. 2016; 22: 583–584. https://doi.org/10.1016/j.cmi.2016.03.030 PMID: 27064135

16. Vasconcelos PF da C, Travassos da Rosa AP de A, Travassos da Rosa JFS, Dégallier N. Concomitant Infections by Malaria and Arboviruses in the brazilian Amazon Region. Rev Latinoam Microbiol. 1990; 32: 291–4. https://doi.org/10.1016/S0037-8682(20)1000500007 PMID: 21085859

17. Service MW. Encyclopedia of arthropod-transmitted infections of man and domesticated animals. Encyclopedia of arthropod-transmitted infections of man and domesticated animals. CABI; 2001. https://doi.org/10.1079/9780851994733.0000

18. Jo WK, Pfankuche VM, Lehmecker A, Martina B, Rubio-Garcia A, Becker S, et al. Association of batai virus infection and encephalitis in Harbor Seals, Germany, 2016. Emerg Infect Dis. 2018; 24: 1691–1695. https://doi.org/10.3201/eid2409.171829 PMID: 30124416

19. Metselaar D, Henderson B, Kirya G, Tukei P, de Geus A. Isolation of Arboviruses in Kenya, 1966–1971. Trans R Soc Trop Med Hyg. 1974; 68: 1966–1971.

20. Tauro LB, Rivarola ME, Lucca E, Muzzin R, Cardoso JF, et al. First isolation of Bunyamwera virus (Bunya viridae family) from horses with neurological disease and an abortion in Argentina. Vet J. 2015; 206: 111–114. https://doi.org/10.1016/j.tvjl.2015.06.013 PMID: 26183295

21. Wilson MR, Suan D, Duggins A, Schubert RD, Khan LM, Sample HA, et al. Association of batai virus infection and encephalitis in Harbor Seals, Germany, 2016. Emerg Infect Dis. 2018; 24: 1691–1695. https://doi.org/10.3201/eid2409.171829 PMID: 30124416

22. Sexton DJ, Rollin PE, Breitschwerdt EB, Corey GR, Myers SA, Dumais MR, et al. Life-threatening cache valley virus infection. New England Journal of Medicine Massachusetts Medical Society; Feb 20, 1997 pp. 547–549. https://doi.org/10.1056/NEJM199702203360804 PMID: 9023091

23. Nguyen NL, Zhao G, Hull R, Shelly MA, Wong SJ, Wu G, et al. Cache valley virus in a patient diagnosed with aseptic meningitis. J Clin Microbiol. 2013; 51: 1966–9. https://doi.org/10.1128/JCM.00252-13 PMID: 23515536

24. Campbell GL, Mataczynski JD, Reisdorf ES, Powell JW, Martin DA, Lambert AJ, et al. Second human case of Cache Valley virus disease. Emerg Infect Dis. 2006; 12: 854–856. https://doi.org/10.3201/eid1205.051625 PMID: 16704854

25. Woodall JP. Human infections with arboviruses of the Bunyamwera group Arboviruses. 1969. pp. 317–332.

26. Pinheiro F, Travassos da Rosa APA, Freitas R. Aspectos clinico-epidemiológicos. Ministério da Saúde (BR) Fundação Serviços de Saúde Pública Instituto Evandro Chagas: 50 anos de contribuição às ciências biológicas e à medicina tropical. 1986. pp. 375–408.

27. Chippaux A, Chippaux-Hyppolite C, Clergeaud P, Brés P. Isolation of 2 human strains of Ilesha virus in the Central African Republic. Bull la Soc medicale d’Afrique noire Lang Fr. 1969; 14: 88–92. PMID: 5399299

28. Beran GW. Handbook of Zoonoses, Section B: Viral Zoonoses. 2017.

29. Emmons RW, Woodie JD, Laub RL, Oshiro LS. Main Drain virus as a cause of equine encephalomyelitis. J Am Vet Med Assoc. 1983; 183: 555–558. PMID: 6413468

30. McGowan JE, Bryan JA, Gregg MB. Surveillance of arboviral encephalitis in the united states, 1955–1971. Am J Epidemiol. 1973; 97: 199–207. https://doi.org/10.1093/oxfordjournals.aje.a121500 PMID: 4692993

31. Bigler WJ, Lassing E, Hoff GL. Arbovirus surveillance in Florida: wild vertebrate studies 1965–1974. J Wildl Dis. 1975; 11: 348–356. https://doi.org/10.7589/0090-3558-11.3.348 PMID: 1152173

32. Vascconcelos PFC, Travassos da Rosa APA, Dégallier N, Rosa JFS T da, Pinheiro F. Clinical and ecopidemiological situation of human arboviruses in Brazilian Amazonia. Cienc Cult. 1992; 44: 117–124.

33. Hammon WM, Reeves WC. Califórnia encephalitis virus, a newly described agent. Calif Med. 1952; 77: 303–309. PMID: 13009479

34. Eldridge BF, Glaser C, Pedrin RE, Chiles RE. The first reported case of California encephalitis in more than 50 years. Emerg Infect Dis. 2001; 7: 451–452. https://doi.org/10.3201/eid0703.010316 PMID: 11394526
37. Putkuri N, Kantele A, Levanov L, Kivistö I, Brummer-Korvenkontio M, Vaheri A, et al. Acute human \inkoo and chatanga virus infections, Finland. Emerg Infect Dis. 2016; 22: 810–817. https://doi.org/10.3201/eid2205.151015 PMID: 27088268

38. Demikhov VG, Chaltsev VG. Neurologic characteristics of diseases caused by Inkoo and Tahyna viruses. Vopr Virusol. 1995; 40: 21–25. PMID: 7740783

39. Kolobukhina LV, Lvov DK, Skvortsova TM, Butenko AM, Gromashevskii VL, Lvov SD, et al. Diseases associated with viruses of the California encephalitis serogroup, in Russia. Vopr Virusol. 1998; 43: 14–17. PMID: 9559529

40. ArboNET. La Crosse virus neuroinvasive disease cases reported by year. 2020.

41. Kinsella CM, Paras ML, Smole S, Mehta S, Ganesh V, Chen LH, et al. Jamestown Canyon virus in Massachusetts: clinical case series and vector screening. Emerg Microbes Infect. 2020; 9: 903–912. https://doi.org/10.1080/22221751.2020.1756697 PMID: 32302268

42. Thompson WH, Kalfayan B, Anslow RO. Isolation of California encephalitis group virus from a fatal human illness. Am J Epidemiol. 1965; 81: 245–253. https://doi.org/10.1093/oxfordjournals.aje.a120512 PMID: 14261030

43. Black SS, Harrison LR, Pursell AR, Cole JR, Appel MJ, Shope RE, et al. Necrotizing panencephalitis in puppies infected with La Crosse virus. J Vet Diagn Invest. 1994; 6: 250–254. https://doi.org/10.1177/10406387940060218 PMID: 8068759

44. Tatum LM, Bossart GD, Altman NH, Pacy JM, Weege JF, Frazier KS, et al. Canine LaCrosse viral meningoencephalomyelitis with possible public health implications. J Vet Diagnostic Invest. 1999; 11: 184–188. https://doi.org/10.1177/10406387991100216 PMID: 10098695

45. Meier-Stephenson V, Langley JM, Drebot M, Artsoh H. Encephalitis in the summer: a case of snowshoe hare (California serogroup) virus infection in Nova Scotia. Can Commun Dis Rep. 2007; 33: 23–26. PMID: 18161204

46. Lynch JA, Binnington BD, Artsob H. Californi a serogroup virus infection in a horse with encephalitis. J Am Vet Med Assoc. 1985; 186: 389. PMID: 3972700

47. Heath SE, Artsoh B, Bell RJ, Harland RJ. Equine encephalitis caused by snowshoe hare (California serogroup) virus. Can Vet J. 1989; 30: 669–671. PMID: 17423397

48. Srithongse S, Grayson MA, Deibel R. California serogroup viruses in New York State: The role of subtypes in human infections. Am J Trop Med Hyg. 1984; 33: 1218–1227. https://doi.org/10.4269/ajtmh.1984.33.1218 PMID: 6507732

49. Osmer EC, Rupprecht CE, Olson JG, Ksiazek TG, Rollin PE, Niezgoda M, et al. Isolation of Kaeng Khoi virus from dead Chaeorephon plicata bats in Cambodia. J Gen Virol. 2003; 84: 2685–2689. https://doi.org/10.1099/vir.0.19294-0 PMID: 13679602

50. Inaba Y, Kurogi H, Omori T. Akabane Disease: Epizootic Abortion, Premature Birth, Stillbirth and Congenital Arthrogryposis-Hydranencephaly in Cattle, Sheep and Goats Caused By Akabane Virus. Aust Vet J. 1975; 51: 584–585. https://doi.org/10.1111/j.1751-0813.1975.tb05538.x PMID: 687271

51. The Center for Food Security & Public Health. Ains Disease. 2018 [cited 20 Jan 2020]. Available: http://www.cfsph.iastate.edu/Factsheets/pdfs/ains_disease.pdf

52. The Center for Food Security & Public Health. Akabane Disease. 2018 [cited 20 Jan 2020]. Available: http://www.cfsph.iastate.edu/Factsheets/pdfs/akabane.pdf

53. Inaba Y, Kurogi H, Omori T. Akabane Disease: Epizootic Abortion, Premature Birth, Stillbirth and Congenital Arthrogryposis-Hydranencephaly in Cattle, Sheep and Goats Caused By Akabane Virus. Aust Vet J. 1975; 51: 584–585. https://doi.org/10.1111/j.1751-0813.1975.tb05538.x PMID: 687271

54. Honda S, Akiyama M, Shimizu M, Fujita A, Med NI-HJV, 2013 U. Swine cases of Akabane virus infection. Hiroshima J Vet Med. 2013; 28: 47–52.

55. Santos RI, Zio L, Bueno-Ju´nior S, Ruggiero RN, Almeida MF, Silva ML, et al. Spread of Oropouche Virus into the Central Nervous System in Mouse. Viruses. 2014; 6: 3827–3836. https://doi.org/10.3390/v6103827 PMID: 25310583

56. Herder V, Wohlesein P, Peters M, Hansmann F, Baumgärtner W. Salient Lesions in Domestic Ruminants Infected With the Emerging So-called Schmallenberg Virus in Germany. Vet Pathol. 2012; 49: 588–591. https://doi.org/10.1177/0300985812447831 PMID: 22610033

57. Sedda L, Rogers DJ. The influence of the wind in the Schmallenberg virus outbreak in Europe. Sci Rep. 2013; 3. https://doi.org/10.1038/srep03361 PMID: 24285292

58. Hirashima Y, Kitahara S, Kato T, Shirafuji H, Tanaka S, Yanase T. Congenital malformations of calves infected with shamonda virus, Southern Japan. Emerg Infect Dis. 2017; 23: 993–996. https://doi.org/10.3201/eid2306.1611946 PMID: 28518043
59. Golender N, Brenner J, Valdman M, Khinch Y, Bumbarov V, Panshin A, et al. Malformations caused by Shuni virus in ruminants, Israel, 2014–2015. Emerg Infect Dis. 2015; 21: 2267–2268. https://doi.org/10.3201/eid2112.150804 PMID: 26583957

60. Golender N, Bumbarov V, Assisi I, Beer M, Khinch Y, Koren O, et al. Shuni virus in Israel: Neurological disease and fatalities in cattle. Transbound Emerg Dis. 2019; 66: 1126–1131. https://doi.org/10.1111/tbed.13167 PMID: 30864252

61. van Eeden C, Williams JH, Gerdes TGH, van Wilpe E, Viljoen A, Swanepoel R, et al. Shuni Virus as Cause of Neurologic Disease in Horses. Emerg Infect Dis. 2012; 18: 318–321. https://doi.org/10.3201/eid1802.111403 PMID: 22305525

62. Shivaprasad HL, Woolcock PR, McFarland MD, Curtis M, Karabatsos N. Turlock-like bunyavirus associated with encephalomyelitis and myocarditis in an ostrich chick. J Vet Diagnostic Investig. 2002; 14: 363–370. https://doi.org/10.1002/jmv.24722 PMID: 11708311

63. Demikhov VG. Outcomes and prediction in diseases caused by Inkoo and Tahyna viruses. Vopr Virusol. 1995; 40: 72–74. PMID: 7762235

64. Shchetin AM, Lyov DK, Deribain PG, Botikov AG, Gitelman AK, Kuhn JH, et al. Genetic and Phylogenetic Characterization of Tatagouine and Witwatersrand viruses and Other Orthobunyaviruses of the Anophèles A, Capim, Guamú, Koongol, Mapputta, Tete, and Turlock Serogroups. Viruses. 2015; 7: 5987–6008. https://doi.org/10.3390/v7112918 PMID: 26610546

65. Centers for Disease Control and Prevention. ArboCat Catalog. [cited 12 Aug 2020]. Available: https://www.cdc.gov/arbocat/

66. Putkuri N, Kurkela S, Levanov L, Huhtamo E, Vaheri A, Sironen T, et al. Isolation and characterization of a California encephalitis serogroup orthobunyavirus from Finnish mosquitoes. Infect Genet Evol. 2014; 22: 164–173. https://doi.org/10.1016/j.meegid.2014.01.023 PMID: 24480054

67. Veronesi E, Henstock M, Gubbins S, Batten C, Manley R, Barber J, et al. Implicating Culicoides Biting Midges as Vectors of Schmallenberg Virus Using Semi-Quantitative RT-PCR. Michel K, editor. PLoS One. 2013; 8: e57747. https://doi.org/10.1371/journal.pone.0057747 PMID: 23520481

68. Mouchantat S, Wernike K, Lutz W, Hoffmann B, Ulrich RG, Böner K, et al. A broad spectrum screening of Schmallenberg virus antibodies in wildlife animals in Germany. Vet Res. 2015; 46: 99. https://doi.org/10.1186/s13567-015-0232-x PMID: 26394618

69. James NM, Edward JD, Stephen WB, David ES. Fenner's Veterinary Virology (Fifth Edition): Chapter 22—Bunyaviridae. Fenner's Vet Virol. 2017; 411–424. https://doi.org/10.1016/B978-0-12-800946-8.00022-2

70. de Souza Luna LK, Rodrigues AH, Santos RIM, Sesti-Costa R, Criado MF, Martins RB, et al. Oropouche virus is detected in peripheral blood leukocytes from patients. J Med Virol. 2017; 89: 1108–1111. https://doi.org/10.1002/jmv.24722 PMID: 27787907

71. Kurogi H, Inaba Y, Goto Y, Miura Y, Takahashi H, Sato K, et al. Serologic evidence for etiologic role of Akabane virus in epizootic abortion-arthrogryposis-hydranencephaly in cattle in Japan, 1972–1974. Arch Virol. 1975; 47: 71–83. https://doi.org/10.1007/BF01315594 PMID: 11708311

72. Kurogi H, Inaba Y, Takahashi E, Sato K, Satoda K. Congenital abnormalities in newborn calves after inoculation of pregnant cows with Akabane virus. Infect Immun. 1977; 17: 338–343. https://doi.org/10.1128/IAI.17.2.338-343.1977 PMID: 892909

73. Godsey MS, Amoo F, Yuill TM, Defoliart GR. California serogroup virus infections in Wisconsin domestic animals. Am J Trop Med Hyg. 1988; 39: 409–416. https://doi.org/10.4269/ajtmh.1988.39.409 PMID: 3189702

74. McJunkin JE, Khan R, de los Reyes EC, Parsons DL, Minnich LL, Ashley RG, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics. 1997; 99: 261–267. https://doi.org/10.1542/peds.99.2.261 PMID: 9024460

75. Wurtz R, Paleologos N. La Crosse Encephalitis Presenting Like Herpes Simplex Encephalitis in an Immunocompromised Adult. Clin Infect Dis. 2000; 31: 1113–1114. https://doi.org/10.1086/321804 PMID: 11048901

76. Uchinuno Y, Noda Y, Ishibashi K, Nagasue S, Shirakawa H, Nagano M, et al. Isolation of Aino Virus from an Aborted Bovine Fetus. J Vet Med Sci. 1998; 60: 1139–1140. https://doi.org/10.1292/jvms.60.1139 PMID: 9819769

77. Tsuda T, Yoshida K, Ohashi S, Yanase T, Sueyoshi M, Kamimura S, et al. Arthropogryposis, hydrencephaly and cerebellar hypoplasia syndrome in neonatal calves resulting from intrauterine infection with Aino virus. Vet Res. 2004; 35: 531–538. https://doi.org/10.1051/vetres:2004029 PMID: 15369656

78. Noda Y, Uchinuno Y, Shirakawa H, Nagasue S, Nagano N, Ohe R, et al. Aino virus antigen in brain lesions of a naturally aborted bovine fetus. Vet Pathol. 1998; 35: 409–411. https://doi.org/10.1177/030098589803500511 PMID: 9754547
79. Southam CM, Moore AE. West Nile, Ilheus, and Bunyamwera Virus Infections in Man. Am J Trop Med Hyg. 1951; 31: 724–741. https://doi.org/10.4269/ajtmh.1951.s1-31.724 PMID: 14894758

80. Chung SI, Livingston CW, Edwards JF, Gauer BB, Colission EW. Congenital malformations in sheep resulting from in utero inoculation of Cache Valley virus. Am J Vet Res. 1990; 51: 1645–8. PMID: 2122779

81. Wernike K, Breithaupt A, Keller M, Hoffmann B, Beer M. Schmallenberg Virus Infection of Adult Type I Interferon Receptor Knock-Out Mice. PLoS One. 2012; 7: 40380. https://doi.org/10.1371/journal.pone.0040380 PMID: 22792298

82. Hahn K, Habierski A, Herder V, Wohlsein P, Peters M, Hansmann F, et al. Schmallenberg virus in central nervous system of ruminants. Emerg Infect Dis. 2013; 19: 154–155. https://doi.org/10.3201/eid1901.120764 PMID: 23260872

83. van den Brom R, Luttikholt SJ, Lievaart-Peterson K, Peperkamp NH, Mars MH, van der Poel WH, et al. Epizootic of ovine congenital malformations associated with Schmallenberg virus infection. Tijdschr Diergeneesk. 2012; 137: 106–111. PMID: 22393844

84. Huang C, Campbell W, Grady L, Kirouac I, LaForce FM. Diagnosis of Jamestown Canyon encephalitis by polymerase chain reaction. Clin Infect Dis. 1999; 28: 1294–1297. https://doi.org/10.1086/514789 PMID: 10451169

85. de Souza Bastos M, Tadeu Moraes Figueiredo L, Gomes Naveca F, Lins Monte R, lia Lessa N, Maria Pinto de Figueiredo R, et al. Short Report: Identification of Oropouche Orthobunyavirus in the Cerebrospinal Fluid of Three Patients in the Amazonas, Brazil Michele. 2012; 86. https://doi.org/10.4269/ajtmh.2012.11–0485

86. Vernal S, Martini CCR, da Fonseca BAL. Oropouche Virus–Associated Aseptic Meningoencephalitis, Southeastern Brazil. Emerg Infect Dis. 2019; 25: 380–382. https://doi.org/10.3201/eid2502.181189 PMID: 30666950

87. Rodrigues AH, Santos RI, Arisi GM, Bernardes ES, Silva ML, Rossi MA, et al. Oropouche virus experimental infection in the golden hamster (Mesocricetus auratus). Virus Res. 2011; 155: 35–41. https://doi.org/10.1016/j.virusres.2010.08.009 PMID: 20727376

88. Lau L, Wudel B, Kadkhoda K, Keynan Y. Snowshoe Hare Virus Causing Meningoencephalitis in a Young Adult From Northern Manitoba, Canada. Open Forum Infect Dis. 2017; 4. https://doi.org/10.1093/ofid/ofx150 PMID: 28948178

89. Edwards JF, Karabatsos N, Collisson EW, De La Concha Bermejillo A. Ovine fetal malformations induced by in utero inoculation with Main Drain, San Angelo, and LaCrosse viruses. Am J Trop Med Hyg. 1997; 56: 171–176. https://doi.org/10.4269/ajtmh.1997.56.171 PMID: 9080876

90. Demikhov VG, Chaitsev VG, Butenko AM, Nedylaikova MS, Morozova TN. California serogroup virus infections in the Ryazan region of the USSR. Am J Trop Med Hyg. 1991; 45: 371–376. https://doi.org/10.4269/ajtmh.1991.45.371 PMID: 1928573

91. Behbehani AM, Hiller MS, Lenahan MF, Wenner HA. Responses of monkeys to California encephalitis, Sicilian sand-fly, and Turlock arboviruses. Am J Trop Med Hyg. 1967; 16: 63–73. https://doi.org/10.4269/ajtmh.1967.16.63 PMID: 4960485

92. Grabow JD, Matthews CG, Chun RWM, Thompson WH. The electroencephalogram and clinical sequelae of california arbovirus encephalitis. Neurology. 1969; 19: 394–404. https://doi.org/10.1212/WNL.19.4.394 PMID: 4975837

93. Granerod J, Tam CC, Crowcroft NS, Davies NWS, Borchart M, Thomas SL. Challenge of the unknown: A systematic review of acute encephalitis in non-outbreak situations. Neurology. Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology; 2010. pp. 924–932. https://doi.org/10.1212/WNL.0b013e3181f11d65 PMID: 20820004

94. Savard M, Paradis A, Francoeur CL. Jamestown Canyon encephalitis with NORSE and electrographic response to ribavirin: a case report. Epilepsia Open. 2018; 3: 286–289. https://doi.org/10.1002/epio.21113 PMID: 29881809

95. Huang C, Thompson WH, Karabatsos N, Grady L, Campbell WP. Evidence that fatal human infections with La Crosse virus may be associated with a narrow range of genotypes. Virus Res. 1997; 48: 143–148. https://doi.org/10.1016/s0168-1702(97)01437-8 PMID: 9175252